Overview

An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Status:
Enrolling by invitation

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

This is a Phase 3, open-label, extension study to assess the long term efficacy and safety of lirentelimab given monthly.

Phase:

Phase 3

Details

Lead Sponsor:

Allakos, Inc.